UK launch for Novo’s new diabetes pill
Rybelsus is the world’s first and only oral GLP-1 receptor agonist
Read More
Tag: Novo
Novo Nordisk launches social responsibility strategy for diabetes
The Defeat Diabetes includes a number of initiatives to provide access to affordable care to vulnerable patients and accelerate prevention to halt the rise of the disease
Read More
Novo, Oxford Uni set to launch diabetes alliance and research labs
Novo Nordisk and the University of Oxford are poised to begin ground-breaking work on therapeutic targets for type II diabetes with new research facilities set to open next week.
Read More
Novo’s oral semaglutide bests MSD’s Januvia on HbA1c reduction
Novo Nordisk has presented data from a Phase IIIa study showing that an oral formulation of its GLP-1 analogue semaglutide was better at reducing blood sugar than MSD’s DPP-4 inhibitor Januvia in patients with type II diabetes.
Read More
Novo makes second move on Ablynx
Novo Nordisk is switching up a gear its efforts to acquire Belgian biopharma Ablynx, with a heightened offer valued at around 2.6 billion euros.
Read More
Novo bags first approval for once-weekly diabetes drug
Novo Nordisk has garnered its first global approval for its once-weekly diabetes therapy Ozempic in the US.
Read More
Novo files once-weekly GLP-1 analogue semaglutide
Novo Nordisk has filed its once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide with regulators on both sides of the Atlantic, seeking permission to market the drug for the treatment of adults with type II diabetes.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
